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Summary  
This review describes the most commonly used rodent models and outcome measures in 
pre-clinical stroke research and discusses their strengths and limitations. Most models 
involve permanent or transient middle cerebral artery occlusion with therapeutic agents 
tested for their ability to reduce stroke-induced infarcts and improve neurological deficits. 
Many drugs have demonstrated pre-clinical efficacy but, other than thrombolytics, which 
restore blood flow, none have demonstrated efficacy in clinical trials. This failure to 
translate efficacy from bench to bedside is discussed alongside achievable steps to improve 
the ability of preclinical research to predict clinical efficacy: 1. Improvements in study 
quality and reporting. Study design must include randomisation, blinding and pre-defined 
inclusion/exclusion criteria and journal editors have the power to ensure statements on 
these and mortality data are included in pre-clinical publications.; 2. Negative and neutral 
studies must be published to enable pre-clinical meta-analyses and systematic reviews to 
more accurately predict drug efficacy in man; 3. Pre-clinical groups should work within 
networks and agree on standardised procedures for assessing final infarct and 
functional outcome.  This will improve research quality, timeliness and translational 
capacity ; 4. Greater uptake and improvements in non-invasive diagnostic imaging to 
detect and study potentially salvageable penumbral tissue, the target for acute 
neuroprotection. Drug effects on penumbra lifespan studied serially, followed by 
assessment of behavioural outcome and infarct within in the same animal group, will 
increase the power to detect drug efficacy pre-clinically.  Similar progress in detecting 
drug efficacy clinically will follow from patient recruitment into acute stroke trials 
based on evidence of remaining penumbra.  
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ADC, apparent diffusion coefficient 
AMPA, Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid 
BCCAO, bilateral common carotid artery occlusion 
CBF, cerebral blood flow 
CCAO, common carotid artery occlusion 
CMRO2, cerebral metabolic rate of oxygen 
DWI, diffusion-weighted imaging 
HMPAO, Hexamethylpropyleneamine Oxime 
MCAO, middle cerebral artery occlusion 
NMDA, N-Methyl-D-Aspartate 
OEF, oxygen extraction fraction 
PET, positron emission tomography 
PWI, perfusion-weighted imaging 
rt-PA, recombinant tissue plasminogen activator 
TTC, Triphenyltetrazolium chloride 
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Stroke – some facts & figures 
 
Stroke is a common and devastating disease. It is the second leading cause of death after 
coronary heart disease in developed countries (Donnan et al., 2008) and is the greatest 
cause of disability, leaving 50% of survivors permanently disabled.  Identification of risk 
factors such as arterial hypertension, high cholesterol, diabetes and obesity have led to 
successful stroke prevention strategies (McArthur and Lees 2010).   Some progress has 
been made in effective rehabilitation following the acute stroke period (Langhorne, 
et al., 2009, Kalra, 2010) with evidence for improvements in motor recovery 
associated with high intensity and  repetitive task-specific practice (e.g. constraint-
induced movement therapy).   However, there is insufficient data at present to 
identify specific interventions which would be widely applicable.    The area which 
has progressed least in the last 15 years, despite a significant pre-clinical and clinical 
research effort is identification of acute therapies which can limit stroke-induced 
brain damage and disability.  There is still no clinically effective neuroprotective 
drug licensed for stroke. 
 
Strokes are classified as haemorrhagic or occlusive/ischaemic, with the majority (80%) 
falling into the latter category (Heiss, 2010).    For occlusive stroke, thrombolysis with 
recombinant tissue plasminogen activator (rt-PA), and care provided by specialised 
acute stroke units, have been proven to improve outcome (Donnan et al., 2008).  
Rt-PA is directed at the occluding blood clot and by enhancing the endogenous formation 
of plasmin from plasminogen, helps dissolve the clot by disruption of fibrin thereby 
enabling restoration of blood flow to ischaemic tissues.  However, it does not offer any 
 4
direct protection to ischaemic tissues, and in fact has neurotoxic potential within the 
parenchyma if not confined within the vasculature (Yepes et al., 2009).  Since 
thrombolysis with rt-PA, also carries a risk of symptomatic intracranial haemorrhage 
(~2%), and probability of benefit declined rapidly with time  beyond 4.5 post- stroke 
(Lees et al., 2010, Hacke et al., 2008, NINDS & Stroke rt-PA Stroke Study Group, 1995) 
guidelines recommend treatment restricted to the first 4.5 hours following stroke onset 
(del Zoppo et al., 2009, ESO, 2008).  In England, Wales and Northern Ireland, only 
3.8% of patients are reported to receive the treatment (Royal College of Physicians, 
2010 National Sentinel Audit of Stroke).  Similar figures are reported in the US 
(~2% of eligible patients, Kleindorfer, et al., 2008) leaving the majority of stroke 
patients with no access to effective drug treatments. 
 
Targeting the ischaemic cascade 
The last 30 years have seen significant progress in our understanding of the 
pathophysiology of ischemic stroke and the identification of mechanisms that contribute 
to tissue damage.  The ischaemic cascade, starting with a severe focal reduction in 
cerebral blood flow (CBF) and culminating in cell death and infarction, has many 
intervening and interlinking  steps which have provided a number of potential drug 
targets (reviewed in Moskowitz,  et al., 2010).  Pharmacological agents have been 
developed to block the major mediators of injury: high, toxic concentrations of 
extracellular glutamate, intracellular calcium and free radicals.   Ischaemia causes 
widespread cellular depolarisation, with Na+, K+, Ca2+ and Cl- fluxes through 
activated ionotropic receptors and gated ion channels, loss of ionic concentration 
gradients across cell membranes, uncontrolled neurotransmitter release and 
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glutamate-induced excitotoxicity.   Calcium dysregulation is the trigger for 
enzymatic destruction of the cell and its components with activation of proteases, 
lipases and nucleases. Activation of enzymes such as neuronal nitric oxide synthase, 
NADPH oxidase, cyclo-oxygenase and lipo-oxygenase generates free radicals which 
attack cellular membranes and dismantle key functions of the cell such as ATP 
production, protein synthesis and the sequestration and storage of intracellular 
calcium within intracellular organelles. Inflammation represents another key 
component of the ischaemic cascade with pro-inflammatory phospholipase A2 
liberating arachidonic acid, a substrate for cyclo-oxygenase and lipo-oxygenase and 
precursor of prostaglandins and leukotrienes.    The culmination of this complex, 
self generating programme of events is either rapid necrotic cell death or delayed 
apoptotic cell death depending on the severity and duration of ischaemia. Drug 
targets include neurotransmitter receptors and ion-channels, free radicals, cytokines and 
inflammatory mediators, enzymes and membranes. Drugs developed to block these 
targets are often referred to as “neuroprotective”.  However, their role is  not simply 
to protect the neurone (i.e. cell body, axon and nerve terminals), but rather  the 
neurovascular unit: the neurone plus the supporting  glial and vascular cells within 
its immediate environment which includes astrocytes, pericytes, microglia, 
oligodendrocytes and the endothelial cells of microvessels (del Zoppo,2010,  
Moskowitz et al, 2010).  A number of drugs have demonstrated neuroprotective efficacy 
in pre-clinical studies where focal ischaemic insults produce reproducible infarcts 
and behavioural deficits(O’Collins et al., 2006). However, human stroke is a highly 
heterogeneous condition and treatment targeted at a single mechanism in the 
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ischaemic cascade is unlikely to be universally effective. Combination therapy, or 
single drugs with multiple targets and actions are more likely to be effective. 
 
Pre-clinical stroke research 
Pre-clinical stroke research is carried out using in vitro and in vivo models. In vitro 
studies use neuronal or mixed cell cultures and organotypic slice preparations as model 
systems which recreate some of the consequences of a focal ischaemic insult.  Cells and 
tissues are exposed to excitotoxic concentrations of glutamate, NMDA, AMPA, Kainate, 
hypoxia or oxygen glucose deprivation.  Compounds are tested for their ability to 
reduce cell death and inhibit the targeted deleterious mechanism (Richard, et al., 
2010) and the most effective are then taken forward for in vivo evaluation.  
Stroke is studied in animal models by permanently or transiently occluding a 
cerebral artery which causes a severe reduction in CBF in the territory of that 
artery. In other words, a focal ischaemic insult is induced in a defined region of 
brain tissue.   This is different from a global ischaemic insult, where the entire brain 
or forebrain is exposed to a severe reduction in its blood supply (e.g. as a 
consequence of cardiac arrest, severe hypotension or peripheral haemorrhage, 
strangulation or drowning).  Animal models of both global and focal ischaemia have 
been developed and reveal differences in the mechanisms of injury and patterns of 
brain damage (reviewed in Ginsberg & Busto, 1989; Traystman, 2003).  
 
Models of focal cerebral ischaemia have been established in a number of species, most 
commonly in lysencephalic species such as rats and mice. Guidelines for drug 
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development recommend that once efficacy is established in rodents, studies are carried 
out in gyrencephalic species such as cats, pigs and non-human primates before taking the 
drug through to studies in man (STAIR, 1999). The current review focuses specifically 
on rodent models of focal cerebral ischaemia.  Rodents are the species of first choice for 
a number of reasons.  It is generally considered ethically more acceptable to use rodents 
rather than higher mammals. Animal and maintenance costs are low and the vascular 
anatomy is similar to man.  Rodent neuroanatomy and the cascade of molecular 
mechanisms leading to ischaemic cell death are well characterised with additional 
information from stroke studies in transgenic mice where specific genes are 
overexpressed or knocked out/down.  Rodent strains and transgenic mice developed 
to display comorbidities such as hypertension, atherosclerosis, diabetes and obesity 
are also available.    Relevance to human stroke is supported by the knowledge that 
these mechanisms are similar between rodents and man and that thrombolysis, the one 
treatment known to be efficacious in man, is equally efficacious in rodent focal 
ischaemia models (Back et al, 2007).  
  
Selection of the model 
 
A wide range of rodent focal cerebral ischaemia models are available for preclinical 
drug development and selection of the most pertinent model will depend on the class 
of drug under study and its perceived mechanism of action. For example, embolic 
stroke models are used to test new thrombolytic drugs, models of transient focal 
ischaemia are commonly used to test free radical scavengers and anti-inflammatory 
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agents and the first glutamate antagonists  to be developed were tested in models of 
permanent focal ischaemia.  However, given the heterogeneity of human stroke, 
drugs should demonstrate preclinical efficacy in a range of different models and 
species before being considered for translation through to clinical trials.  
 
Middle cerebral artery occlusion (MCAO). 
The middle cerebral artery (MCA) is the most commonly affected blood vessel in 
human occlusive/ischaemic stroke (Mohr et al., 1986)  and is the artery most 
commonly targeted in rodent stroke models (see Figure 1).  A range of MCAO models 
have been developed and there are advantages and disadvantages associated with each 
approach (Table 1).  Following surgical exposure of the blood vessel via a craniectomy,  
the  MCA can be occluded in a number of ways: by electrocoagulation of the blood 
within it and destruction of the blood vessel per se (Tamura et al, 1981); mechanically, 
by applying an occluding device such as a clip or ligature (van Bruggen et al, 1999); or 
pharmacologically by applying a potent and prolonged vasoconstrictor such as 
endothelin-1 (Macrae et al., 1993).  MCAO models which do not require a craniectomy 
include stereotaxic injection of endothelin-1 into parenchyma adjacent to the MCA which 
results in a longer lasting vasoconstriction (Sharkey et al., 1993).   Alternatively, the skull 
is left intact and an intravascular approach via the carotid artery used to advance a 
filament or embolus to the point where it blocks the origin of the MCA (Koizumi et al., 
1986; Longa et al., 1989; Zhang et al., 1997).   
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MCA occlusion by electrocoagulation or application of an occluding device 
All the models within this category require a craniectomy and section of the dura mater to 
expose the MCA. Models which require a craniectomy are associated with low or absent 
mortality (Table 2) since the craniectomy prevents ischaemia-induced increases in 
intracranial pressure. This can be a significant advantage, particularly where large strokes 
are studied over a number of days.  Oedema and brain swelling correlate with infarct size 
and the increases in brain volume associated with large MCA strokes over the first 24-48 
hours post-stroke would cause significant mortality if the skull was intact.  
 
Following surgical exposure, the MCA is permanently occluded by coagulating the blood 
within it using an electric current passed through the tips of fine diathermy forceps 
(Tamura et al., 1981). The occluded portion of the artery is then cut confirming complete 
occlusion.   Electrocoagulation models have been successfully adapted for use in 
larger species such as the cat (Bullock et al., 1990), miniature pig (Imai et al, 2006) 
and baboon (Yonas et al., 1981).   Maintaining sterile conditions and careful post–stroke 
care of the wound is particularly important to avoid any infection associated with the 
surgery which will  increase ischaemic damage and confound the ability to determine 
drug-induced effects on infarct size and functional recovery.     The main advantages 
of the model are good reproducibility in infarct size and functional deficit, low mortality, 
visual confirmation of successful MCAO and the ability to adapt the model to produce 
infarcts of different size and location.     The main disadvantages are that the model 
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induces permanent focal ischaemia and is not therefore suitable for investigation of 
thrombolytic agents or drugs designed to target the reperfusion phase following 
ischaemia. Inducing MCAO is technically demanding. Exposing the artery and applying 
electrocoagulation without rupturing the blood vessel or damaging the underlying cortex 
requires significant surgical skill.    The surgery required for proximal MCA occlusion 
can also cause jaw alignment problems in rats requiring replacement of standard chow 
with soft diet and regular monitoring and tooth filing to avoid overgrowth.  
 
Alternative MCA occlusion models use devices such as microaneurysm clips, hooks 
(used to lift the artery from the cortical surface until flow ceases), ligatures and in, larger 
species, inflatable cuffs to occlude the artery remotely (Shigeno et al., 1985; van Bruggen 
et al., 1999).  These models have the advantage of control over the duration of ischaemia 
and allow subsequent reperfusion of ischaemic tissue.  They provide visual confirmation 
of successful MCAO and reperfusion when the occluding device is removed.  However, 
microaneurysm clips are too small to apply by hand in rats and have to be loaded into a 
special applicator for attachment to the MCA.  Applying and removing the clips without 
damaging the artery is technically difficult, particularly when targeting the proximal 
MCA. Other disadvantages include greater variability in infarct size compared to 
electrocoagulation models, particularly when a single point on the MCA is occluded. 
Reproducibility is improved by occluding the artery at more than one site, combining 
MCAO with hypotension or ipsilateral common carotid artery occlusion, or using rat 
strains with poor collateral supply (e.g. the spontaneously hypertensive rat and the 
spontaneously hypertensive stroke-prone rat, see Coyle & Jokelainen, 1983) to increase 
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the severity of the ischaemic insult. However, when considering neuroprotection studies, 
it is worth considering that steps such as these taken to improve reproducibility in infarct 
size are also likely to result in less potentially salvageable penumbral tissue being 
available for rescue.  
 
Modifications to the model 
The position and length of MCA occluded provides some control over the severity of the 
ischaemic insult, the amount of penumbral  tissue available for rescue, and the 
neurological deficit produced.  Proximal occlusion of a long segment of the MCA 
including the lenticulostriate branches gives rise to a large consistent ischaemia and 
infarct in cortical and subcortical structures (see electrocoagulation, Figure 1) and a 
reproducible neurological deficit.  However, the greater the volume of ischaemic tissue 
within the MCA territory  the  less penumbral tissue will be available for the drug under 
test to rescue.  Occlusion of a shorter (1-2 mm) segment of the MCA, distal to the inferior 
cerebral vein, will induce a smaller region of ischaemia and infarct, mainly confined to 
the cortex, and provide a larger volume of target penumbral tissue.  However, the 
neurological deficit produced will be much milder and more difficult to detect.       
 
MCA occlusion induced pharmacologically 
 The peptide endothelin-1 (ET-1) lends itself to cerebral ischaemia research because it 
induces profound and prolonged vasoconstriction of cerebral vessels (Asano et al. 1989, 
Robinson and McCulloch 1990). ET-1 topically applied to the abluminal surface of the 
exposed MCA induces an ischaemic insult of sufficient severity and duration to produce 
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a reproducible infarct (Figure 1). This model was developed in the rat (Macrae et al. 
1993) and has been adapted for use in marmosets (Virley et al., 2004).  Advantages 
include visual confirmation of ischaemia, with some control over the severity and 
duration by adjusting the ET-1 concentration, a gradual reperfusion and low mortality.  
Disadvantages include stability and potency issues relating to peptides which can 
increase variability.    An alternative model, where ET-1 is administered by stereotaxic 
injection into piriform cortex immediately adjacent to the proximal MCA, is less 
demanding surgically, and induces a more persistent ischaemia that topical application 
(Figure 1, Sharkey et al. 1993).  This model is more useful for fast throughput screening 
of drugs and has been adapted for induction of stroke in the conscious animal by injecting 
ET-1 via a previously implanted guide cannula. If  endothelin -1 is replaced with 
endothelin-3, it is possible to reverse vasoconstriction and downstream ischaemia 
with a second injection of an endothelin-A receptor antagonist  (Henshall et al., 
1999).  Intraparenchymal injection of ET-1 has been adapted for anterior cerebral 
artery occlusion (Ward et al., 1998) and selective white matter ischaemia in the internal 
capsule (Frost et al., 2006; Lecrux et al., 2008).  
    
MCA occlusion by intraluminal filament 
The intraluminal filament (or suture) method is currently the most widely used model of 
focal ischaemia in rats and mice, and is used to induce both permanent and transient 
ischaemia. No craniectomy is required as the occluding device, a flexible monofilament, 
is introduced directly into the internal carotid artery (or with modification, via the 
external carotid artery) and advanced until it blocks the origin of the MCA (Figure 1).  
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The method was introduced by Koizumi (Koizumi et al. 1986) with the first of many 
modifications described by Longa (Longa et al. 1989).  The advantages of this model are 
the ability to precisely control the duration of ischaemia and the fact it is technically 
easier to master than the craniectomy models. The disadvantages mainly relate to 
difficulties in reproducibility and mortality.  Modifications to improve reproducibility 
include filament construction, coating, & design of the tip, and are covered in a recent 
review (Durukan and Tatlisumak, 2007). Filament diameter is carefully matched to a 
defined body weight range in rodents to ensure adequate occlusion of the origin of the 
MCA. Laser Doppler flowmetry probes, placed on the skull above the sensorimotor 
cortex, are commonly used to guide correct placement of the filament, to assess the 
severity of the drop in CBF and to avoid advancing the filament too far, thereby risking 
blood vessel puncture and haemorrhage. Filament insertion to block the origin of the 
MCA should induce cortical and subcortical ischaemia but tissue infarction may be 
confined to subcortical structures with minimal cortical involvement if the rodent strain 
used has good collateral blood supply to the cortex (Coyle and Jokkelainan, 1983; 
Duverger and Mackenzie, 1988). Increasing the duration of ischaemia, tandem occlusion 
of the carotid artery(s) or hypotension are used to increase cortical involvement.   Since 
the filament is advanced along the internal carotid artery to reach the origin of the MCA, 
depending on filament construction, other arteries which branch off the internal carotid, 
proximal to the origin of the MCA, may also be occluded by the filament.  Therefore, 
although this model is employed for  MCA occlusion, other arteries, such as the anterior 
choroidal and  hypothalamic arteries may also be blocked, leading to damage beyond 
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MCA territory, and corresponding associated deficits (e.g. hyperthermia associated with 
ischaemic damage to hypothalamus, Li et al. 1999).   
For longitudinal studies, problems with morbidity and mortality are encountered when 
ischaemia is permanent or prolonged (e.g. > 90 mins).  This is manifest within the first 
24-48 hours in animals with large MCA territory strokes due to brain swelling and 
increased intracranial pressure (Table 2).   
 
Embolic MCA occlusion models  
Embolic models fall into two main categories: 1. Embolisation induced by the 
introduction of blood clots or artificial emboli; 2. Localised chemically initiated 
thromboembolism. Thromboemboli cause most human strokes and therefore models that 
mimic this type of occlusion are useful for testing new thrombolytic agents. Blood drawn 
from the animal to form autologous clots of specific size and composition ex vivo are 
subsequently (e.g. 24 hours later) introduced into the cerebral circulation via a cannula 
inserted and advanced along the internal carotid artery (using a similar approach to 
intraluminal filament insertion). Longa et al. (1989) first described the induction of 
thromboembolic stroke in the rat, with subsequent modifications published by Busch et 
al.(1997). Similar models have been established in mice (Zhang et al., 1997), rabbits 
(Lapchak et al., 2000), cats (Yamaguchi et al., 2000) and non-human primates (Kito et 
al., 2001, Watanabe et al., 1977).  The advantages of embolic models include their 
clinical relevance, the fact that the surgery required is straightforward and does not 
involve a craniectomy. When the clot is correctly positioned, large infarcts can be 
induced which include both cortical and sub-cortical structures, and give rise to 
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pronounced behavioural deficits.  The blood clot is broken down and reperfusion induced 
by administration of thrombolytics such as recombinant tissue-type plasminogen 
activator (rt-PA). Meta-analysis of the pre-clinical literature demonstrates 
similarities with the clinical literature: rt-PA administered within the first 3-4 hours 
post-stroke in rodents reduces infarct volume and improves neurobehavioural 
scores in rats, with an increased probability of haemorrhage (Perel et al., 2007).  
However, quality scores for the 113 studies identified was poor with evidence of 
publication bias.  There are a number of pertinent disadvantages associated with embolic 
models.  Intravascular introduction of emboli can result in multifocal ischaemia with 
significant variability in infarct size and location as well as early autolysis, depending on 
emboli composition (see Busch et al. 1997). Brain haemorrhage is frequent with embolic 
models and mortality rates are generally much higher (e.g. ≥30% in rat) than for other 
models (Table 2).  
Composition and stability of the embolus are important in preventing spontaneous clot 
disintegration. Thrombolytic breakdown of the blood clot and recanalisation of the 
occluded artery is related to the amount of red cells in the emboli and inversely related to 
the volume of the emboli, fibrin content and density of the clots. (Overgaard et al., 1994).  
Since early in vitro studies demonstrated that the rat’s fibrinolytic system was 10-fold 
less sensitive to rtPA than the human system (Korninger and Collen, 1981), the majority 
of in vivo studies have used rt-PA at a 10 fold higher dose (10mg/kg) than the human 
dose (0.9 mgs/kg).  Successfull thrombolysis and reperfusion achieved with 10 mg/kg  rt-
PA administered  within 2-4 hours of stroke reduced infarct size, and improved survival 
and neurological deficits in rodent models. However, the higher dose may not be 
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necessary or recommended  for future pre-clinical research since a recent study, 
comparing the two doses administered 45 minutes after stroke in a rat embolic model, has 
demonstrated that the lower (human) dose was equally effective in inducing reperfusion 
(although slower in onset) and significantly reduced infarct size and oedema. (Haelewyn 
et al, 2010).   The 10mg/kg dose is no longer effective beyond 4 hours post-stroke and 
increases infarct size and haemorrhagic transformation (Kano et al, 2000, Lapchak et al., 
2010). 
 
Artificial emboli 
A variety of materials have been used to form non-clot emboli (see Durukan and 
Tatlisumak 2007), the most common being microspheres of defined diameter. 
Suspensions of calibrated microspheres injected into the internal carotid artery produce 
microembolisation and slowly evolving ischaemic lesions and a model in rabbits has been 
used for the study of stroke pharmacotherapy (Zivin et al. 1987).  However, the utility of 
microspheres is more limited than clot-based emboli in that vessel occlusion is permanent 
with no potential for recanalisation, either spontaneously or interventionally (Mayzel-
Oreg et al. 2004). 
 
Chemically initiated thromboembolism. 
Chemically initiated thromboembolism is induced photochemically by systemic injection 
of a photosensitive dye (e.g. Rose Bengal or erythrosin B) in combination with irradiation 
through the exposed skull with light of a specific wavelength (Watson et al. 1985, rats; 
Sugimori et al. 2004, mice). The reaction between the light and the intravascular dye 
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generates oxygen radicals causing peroxidation of endothelial lipids and blood elements, 
thereby inducing platelet aggregation and thrombosis (Ginsberg and Busto 1989).  The 
model is minimally invasive, produces a reproducible cortical photothrombosis in 
both rats and mice and uses specialist laser equipment which provides precision 
over the exact location of ischaemia.  Mortality associated with the model is low and 
the size and depth of ischaemic damage can be controlled by adjusting the plasma 
concentration of the dye and the intensity and duration of light. Limitations of the model 
include its end-arterial occlusive nature which makes the lesion resistant to flow 
enhancement strategies. The rapid progression of ischaemic damage is associated 
with  significant early cytotoxic and vasogenic oedema formation which is different 
from the situation in human stroke.  Early versions of the model induced a severe 
insult with rapidly evolving ischaemic damage and no salvageable penumbral tissue but 
more recent modifications, using a ring model and modified laser parameters, display 
“region-at-risk” in the ring-encircled interior region (Wester et al. 1995, Hilger et al. 
2004).  Further developments include the use of optical fibres stereotaxically  
implanted or directed at the surgically exposed proximal MCA to produce 
photothrombosis in subcortical sites. These models demonstrate evidence of 
penumbra on MRI scans and reversal of ischaemia with rt-PA  (Kuroiwa et al., 
2009, Chen et al., 2007). 
 
Recently, a new model of thromboembolic stroke has been developed in the mouse where 
in situ microinjection of thrombin into a branch of the MCA is used to trigger local clot 
formation (Figure 1, Orset et al. 2007, 2010). A craniectomy is required to expose the 
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MCA branch and insertion of  the tip of a thrombin-filled micropipette into the blood 
vessel. Thrombin injection induces the formation of a clot in situ, a persistent 
downstream ischaemia and a reproducible cortical infarct.  Recanalisation of the occluded 
branch is achievable using intravenous rt-PA (10 mg/kg i.v. administered 20 minutes 
later) with restoration of cortical cerebral blood flow and reduced final infarct size. The 
advantages of this thromboembolic model include more precise control of the location of 
ischaemia and the ability to visually determine the permanency of vessel occlusion, and 
successful recanalisation in thrombolysis studies. The size and location of cortical 
ischaemia and infarction is more reproducible than for the autologous clot models and 
mortality is minimal. Disadvantages include the requirement for a craniotomy, the 
possibility of spontaneous thrombus disruption and reperfusion with microclot formation 
(although this can be identified visually and built into exclusion criteria), and the lack of 
a robust neurological deficit, due to the small cortical lesion.  
 
Outcome measures and endpoints  
The major preclinical outcome measures for stroke pharmacotherapy studies are final 
infarct size (i.e. the amount of permanent brain damage produced by the stroke) and 
neurological deficit (generally sensorimotor deficits induced by MCAO).  The latter is 
the more clinically relevant but also the more challenging to accurately assess in animal 
models as these deficits can rapidly resolve in rodent models.  For flow enhancing and 
thrombolytic drugs, successful recanalisation and the quality of reperfusion are also 
assessed using CBF techniques.  
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Infarct volumes are quantified from histologically stained brain sections (e.g 
haematoxylin and eosin, cresyl violet or tetrazolium salts such as TTC) or non-invasively 
with T2-weighted MRI (Sommer, 2010, Durukan and Tatlisumak, 2007, see Figure 2). 
The infarct develops over a number of hours (permanent MCAO) or days (transient 
MCAO).  Consequently, it is fundamentally important in drug efficacy studies that the 
time point at which the measurement is made is late enough for the infarct to have fully 
evolved.  Otherwise drugs which delay rather than stop the progression of ischaemic 
damage could be wrongly assessed as neuroprotective.  Infarct area is first quantified 
on sufficient numbers of coronal sections throughout the MCA territory to allow 
accurate determination of infarct volume (e.g. 8 slices described in Osborne et al., 
1987 for proximal MCAO induced by electrocoagulation).  However, since brain 
oedema also develops within and around the infarct over the first 2-3 days post-stroke,   
infarct volume calculations should be corrected for the space-occupying effect of 
brain oedema, to avoid overestimation of infarct volume.  Corrections for brain 
swelling are made using published formulae (e.g. Swanson et al, 1990). Infarct 
volume is assessed indirectly as the volume of the contralateral hemisphere minus 
the non-infarcted volume of the ipsilateral hemisphere and is based on the 
assumption that oedema develops almost exclusively within the infarct.  However, 
there are limitations associated with this type of correction.  Tissue sections 
examined at the peak of stroke-induced oedema, clearly show brain swelling in both 
infarct and surrounding peri infarct tissue. Therefore, infarct volume correction 
using these methods may still be confounded by oedema (Dirnagl, 2010).   
Alternative approaches to correct for oedema involve identifying ischaemic damage 
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on tissue sections and transcribing the information onto line diagrams of standard 
size from a stereotaxic atlases (Osborne et al, 1987).   
 
Infarct size can be expressed either as an absolute volume in mm3 or as a relative 
value (e.g. percentage of the contralateral hemisphere, or brain volume). Relative 
values allow more straightforward comparison between studies as absolute brain 
size will vary depending on animal  sex and  age.  Tissue dehydration and processing 
also affects brain size with  different  techniques causing markedly different degrees 
of shrinkage of the tissue (e.g. greater in paraffin embedded that in frozen tissue). For 
chronic studies, where rodents survive >7 days post-stroke, the removal of dead tissue by 
macrophages and microglia results in the infarct being gradually replaced by a fluid-filled 
cyst.  The difference between the volume of the remaining ipsilateral and the contralateral 
hemisphere provides an alternative measurement of tissue loss as a consequence of the 
stroke. 
 
Diffusion-weighted MRI is non-invasive and is particularly useful for serial scanning in 
the acute stroke period (first 3-4 hrs post-stroke). Affected tissue appears hyperintense, 
allowing  tracking of the evolution of ischaemic injury and the consequences of 
therapeutic intervention. However, acute hyperintensity on DWI scans does not 
signify irreversible ischaemic damage as this abnormality can disappear on early 
reperfusion of ischaemic tissue.  Following serial scanning, and anaesthetic withdrawal 
animals can be recovered for behavioural assessment of neurological deficits  at later 
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time points and re-anaesthetised for assessment of final infarct with T2-weighted MRI 
(Ebisu et al, 2001).  
 
Functional outcome represents an essential component of the preclinical testing of drugs 
targeting the acute (neuroprotection) and chronic (repair and recovery) stages of stroke.  
Testing functional outcome is extremely time consuming and labour intensive.   It is still 
an evolving science with groups developing new and modifications of existing tests, with 
no consensus as yet on a prescribed battery of tests to determine stroke outcome. Not 
only are there many different tests being used, but there is no consistency in the 
number and frequency of tests applied within a study. The current lack of consensus 
is a weakness in the field that needs to be addressed if we are to improve the ability 
of animal models to predict therapeutic efficacy in man.   There has to be agreement 
amongst preclinical researchers and guidelines drawn up  on the specific 
sensorimotor tests which offer the best opportunity to identify long-term deficits in 
rodents, the optimum (i.e. minimum) number required and the frequency with 
which the animals should be tested.   
 
The range of behavioural tests developed for quantifying the severity of the sensorimotor 
deficit and the extent of subsequent recovery are covered in recent reviews   (see Metz, 
2010, Schallert, 2006). Specific tests, such as the Morris water maze, are used to 
determine cognitive deficits, which may arise when artery territories other than the 
MCA are affected and more general neurological scoring systems have been developed 
to provide an overall score of the animal’s condition. They  range from simple 0-3 point 
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scores based on forelimb flexion, resistance to lateral push and circling   (Bederson et al., 
1986) to more detailed (3-18 point or 21 point) scoring systems incorporating sensory 
and motor assessments (Garcia et al., 1995, Hunter et al., 2000).  However, scoring 
systems have limited value and  tend to be either fast to carry out but limited in ability to 
differentiate between different levels of deficit or time consuming and over detailed, with 
some of the component parts contributing little to the sensitivity of the method. Hence, 
each group tends to apply further modifications to the published systems to reduce 
the time required to score each animal or to increase sensitivity to pick up a deficit. 
Specific behavioural tests assessing skilled motor function appear more informative and 
clinically relevant.    The most commonly used tests include sensorimotor asymmetry 
(sticky label or dot test), and fore/hindlimb use (e.g. cylinder test, ledged/tapered beam, 
horizontal ladder walking task, Figure 3).  Animals are assessed for ability to undertake 
and complete the tasks (e.g. time taken and order in which sticky labels are removed from 
the affected and normal forelimbs), scored for preference of use of uninjured versus 
injured limb (e.g. cylinder test)  or number of foot faults made in completing a motor task 
(e.g. tapered beam, ladder walking test).  Assessment of functional outcome in rodents is 
challenging as neurological deficits are often not overt, even when the animal sustains a 
large infarct.  Difficulties may be encountered in animal compliance to undertake the 
task, and the deficit may be short-lived, as rodents often exhibit learned compensatory 
behaviour which may be wrongly identified as recovery. However, chronic deficits post 
stroke have been identified with behavioural testing and used to assess the effects of 
therapy on functional outcome.  For example, the whiskers reflex, rotameter test 
with amphetamine and bilateral asymmetry (sticky label) test continue to detect 
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sensorimotor deficits out to 12 weeks from stroke onset (60 minute ischaemia using 
the intraluminal thread model, Modo et al., 2000) and  the sticky label and 
rotameter tests were  sensitive enough to detect improvements in sensorimotor 
deficits  following stem cell injection into the putamen at 4 weeks post-stroke  
(Stroemer et al, 2009).      
  
Cerebral blood flow (CBF) measurement is useful for  determining blood vessel 
recanalisation in thrombolytic studies, identifying drug effects on stroke severity or 
quality of reperfusion, and for confirmating  comparable severities of ischaemic insult 
between groups prior to drug administration.  The main techniques employed in pre-
clinical research are laser Doppler flowmetry and hydrogen clearance, which provide 
good temporal resolution,  [14C] iodoantipyrine and [99m Tc] HMPAO autoradiography, 
terminal techniques with good spatial resolution, and MRI perfusion-weighted imaging 
(PWI) which provides spatial and temporal information on CBF.  Laser Doppler 
flowmetry probes are placed on the surface of the skull or stereotaxically implanted into 
discrete neuroanatomical sites to provide a semi-quantitative read out of change in blood 
flow over time, but data are generated in relative (flux), not absolute units with data 
restricted to a limited volume of tissue around the probe tip.  Autoradiographic 
techniques provide fully quantitative ([14C]-iodopyrine) or semi-quantitative ([99m Tc] 
HMPAO) information on CBF throughout the brain but restricted to a single time point. 
Non-invasive MRI perfusion techniques such as arterial spin labelling requires no 
exogenous contrast agent and can be calibrated to provide fully quantified serial maps of 
CBF (Figure 2d). 
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 The importance of the ischaemic penumbra in pre-clinical and clinical stroke research 
Occlusion of a cerebral artery causes a severe reduction in CBF within the brain territory 
the occluded artery normally supplies. However, because the territories of the major 
cerebral arteries are linked via collateral blood vessels (anastomoses), there is 
heterogeneity of tissue perfusion within the ischaemic region.  Tissue furthest from 
collateral supply and exposed to the most severe reduction in CBF (<20% of baseline) is 
referred to as the “ischaemic core” and becomes irreversibly damaged within minutes as 
ATP supplies are rapidly exhausted. Surrounding the ischaemic core is a border zone 
where collateral flow results in a less severe reduction in CBF. However, CBF levels are 
not sufficient to sustain normal function.  This zone, referred to as the “ischaemic 
penumbra”, has preserved structural integrity but a limited lifespan (of hours), due to the 
inadequate supply of oxygen and glucose, limiting its capacity to generate ATP.  It is 
referred to as “tissue at risk” and “potentially salvageable” as prompt restoration of CBF 
leads to penumbral tissue survival and recovery of function (Symon, 1987, Heiss, 2010).  
Without restoration of blood flow, penumbral tissue gradually becomes incorporated into 
the irreversibly damaged ischaemic core. Penumbral tissue,  detected and followed 
over time using MRI perfusion/diffusion (PWI/DWI) mismatch, becomes gradually 
incorporated  into the ischaemic core over a period of  4-6 hours in rodent 
permanent MCAO models (Meng et al., 2004; McCabe et al, 2009).    Penumbra 
therefore represents the therapeutic target for acute stroke therapies. 
 
In the past, clinical trials were compromised by the lack of penumbra imaging, patients 
being recruited on the basis of time from stroke onset, rather than detection of 
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potentially salvageable tissue. This combined with unrealistically long therapeutic time 
windows meant inclusion of patients with no remaining penumbra who were unlikely to 
benefit from acute stroke therapies, diminishing the power to identify effective drugs. 
The amount of salvageable penumbra varies widely among acute stroke patients. Some 
have no remaining penumbra (or chance to benefit from treatment) even within a few 
hours of stroke, while others may have large amounts of penumbra persisting far longer 
than average.  Consequently, some drugs which demonstrated pre-clinical efficacy but 
subsequently failed in clinical stroke trials may have had clinical efficacy which was 
missed due to the lack of appropriate patient selection (e.g. inclusion of patients with 
large strokes and no remaining penumbra, or small strokes). In clinical trials, using very 
simple brain scanning, the thrombolytic rt-PA reduced death and disability when given 
within 4.5 hours of stroke, with probability of benefit declining rapidly with time 
thereafter (Lees et al., 2010, Hacke et al., 2008, NINDS & Stroke rt-PA Stroke Study 
Group, 1995). However, with more sophisticated imaging, targeting rt-PA treatment to 
those patients with persisting penumbra, the time frame for benefit could be potentially 
extended at least out to 6 hours, since outcomes in the 3-6 hour window with MRI 
selection did not differ from treatment within 3 hours (Kohrmann et al., 2006). 
 
PET imaging (CBF,CMRO2, OEF) is also used to detect penumbra but  low availability, 
high cost and poor spatial resolution limit its utility for routine clinical use and pre-
clinical  rodent studies.  MRI perfusion/diffusion mismatch and CT perfusion imaging are 
being validated for penumbra detection in animal and clinical scanners and will be key in 
identifying effective acute stroke therapies in the future.  MRI provides not only 
longitudinal data on survival of penumbra, but also complementary multiparametric data 
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on the evolution of stroke (Table 3).  However, like the induction of stroke, the use of 
anaesthesia to limit movement during scanning has to be acknowledged as a 
limitation of MRI-based stroke research in animals.  
 
Additional confounding factors and general limitations of stroke studies in rodents  
Generally in neuroprotection studies the drug under test is administered either before, or 
within the first 1-2 hours post-stroke, in order to provide the best opportunity to identify 
efficacy. Although this provides a good first step in identifying promising drugs, there are 
clear limitations in relying on this type of study design to identify drugs/therapies which 
have the potential to translate successfully to the clinic.  The available time window for 
delaying treatment should also be determined.   
 
In the past, most drug efficacy studies were carried out on inbred young, healthy male 
animals expressing none of the comorbidities commonly associated with stroke. The use 
of such animals limits costs and helps control variability in outcome measures such as 
infarct size and sensorimotor deficits.  The failure of drugs, tested only in healthy 
animals, to show efficacy in clinical trials has challenged the relevance of these stroke 
models and highlighted the need for additional pre-clinical efficacy studies in aged (i.e. 
~18 month old for normotensive rat), and female animals, and in animals with relevant 
co-morbidities (i.e. hypertension, diabetes, obesity, infection, inflammation and 
atherosclerosis). However, it is important to recognise that in addition to cost, stroke 
severity, morbidity and mortality are likely to be increased in these models.  The severity 
of the ischaemic insult should therefore be adjusted to a level where morbidity and 
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mortality are within ethically acceptable levels.   Equally important for stroke 
pharmacotherapy studies is the fact that the amount of penumbra is also likely to be less 
than in young, healthy animals.  This will need to be incorporated into power analysis for 
sample size calculation so that studies are not underpowered to detect drug efficacy.   A 
range of rodent disease models incorporating comorbidities and risk factors are available 
(see McColl et al., 2010):- 1. Hypertension: genetically determined hypertensive strains 
such as the spontaneously hypertensive (SHR), spontaneously hypertensive stroke-prone 
rat (SHRSP, also insulin resistant), and models of induced hypertension such as the 
DOCA salt rat; 2. Diabetes: models displaying diabetes/hyperglycaemia include the 
streptozotocin and Biobreeding (BB) rat models and the  non-obese diabetic (NOD) 
mouse models of type-1 diabetes, Zucker and Goto-Kakizaki rat models of type 2 
diabetes and the fructose fed rat model of metabolic syndrome (insulin resistance, 
hyperinsulinemia and hypertension);  3. Obesity: diet-induced obesity can be generated 
with high-fat and high-sugar diets in Sprague-Dawley and Long Evans rats and C57B16/J 
mice. Models incorporating both diabetes and obesity include the Zucker diabetic fatty 
rat, the db/db (spontaneous mutation in leptin receptor gene)  and ob/ob (spontaneous 
mutation in Lep gene encoding the protein leptin) mouse models;  4. Atherosclerosis: 
genetically modified mouse models are most prevalent. The early foam cell/fatty streak 
stage of the disease can be induced in wild-type mice but requires aggressive and 
prolonged (4-5 month) dietary manipulation.  Advanced atherosclerosis can be induced in 
genetically modified murine strains with the addition of dietary modification (e.g. Paigen 
or Western diets). The best characterised of these are the apolipoprotein E (apoE)-/-  and 
low density lipoprotein receptor (LDLR)-/- mouse models. 
 28
 Irrespective of the model to be used, the stroke must be induced in as sterile an 
environment as possible. Although fairly resistant to infection, wound infections can 
occur in rodents, particularly in chronic studies.  This can be avoided by keeping the 
operating area clean and as sterile as possible.  Surgical sites should be shaved and 
disinfected, and instruments and occluding devices (e.g.  intraluminal filaments, 
clips etc.) sterilised prior to use. Surgery-related infections can lead to meningitis and 
significant recruitment of inflammatory cells into the brain, thereby influencing the 
severity of the ischaemic insult and increasing the final infarct size. Infections will also 
increase variability in outcome measures and confound interpretation of drug study 
results.  Since inflammation is also a natural downstream consequence of focal ischaemia 
(Moskowitz et al, 2010, review) it is important to ensure that any inflammation identified 
in the brain is a consequence of the ischaemic insult and not an infectious agent 
introduced as a result of poor aseptic technique.   
 
The lack of white matter in rodents compared to gyrencephalic species and man 
represents another important limitation. However, small ischaemic lesions can be induced 
in the larger white matter tracts (e.g. internal capsule) by stereotaxic injection of 
vasoconstrictor endothelin-1 (Frost et al., 2006, Lecrux et al., 2008).  Quantification of 
white matter damage  is achievable using immunohistochemistry (e.g. amyloid precursor 
protein accumulation at sites of injury, Gentleman et al., 1999, Imai et al., 2002) and MRI 
(e.g. diffusion tensor imaging, Sotak, 2002).      
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Finally, it is important to be aware that certain mouse strains display a high frequency of 
cerebrovascular anomalies leading to an incomplete circle of Willis (Kitagawa et al., 
1998; Kelly et al., 2001).  This will influence the severity of focal ischaemic insults by 
compromising collateral flow and represents a major source of variability in outcome 
measures.   
 
Recommendations for the future 
The failure to predict acute neuroprotective drug efficacy from pre-clinical data has 
led to the relevance of animal stroke models being questioned.  There is some merit 
in this viewpoint.  What are described in this review are NOT in fact rodent models 
of stroke, they are models of focal cerebral ischaemia.  They model the consequences 
of an ischaemic insult but, in the main, do not recreate the background 
pathophysiology which would give rise to an endogenous stroke.  Therefore, we have 
to accept the limitations inherent in these models and, follow early proof of efficacy 
studies in young healthy animals with more rigorous studies in models 
incorporating age and co-morbidities.  Only drugs which demonstrate efficacy in a 
range of these models should be considered for further investigation in larger 
gyrencephalic models and subsequent translation to clinical trials. 
 For drugs targeting the brain, ability to cross the intact blood brain barrier is 
crucial and should be established in animals before the drug progresses through to 
human stroke trials.   
Translational problems will be reduced with further improvement in pre-clinical  
study design and conduct.  A number of substandard practices have been identified 
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and recommendations published to improve the quality and reporting of pre-clinical 
stroke research (STAIR I, 1999 subsequently updated by Fisher et al., 2009, 
Macleod et al., 2009, Kilkenny et al., 2010): study design should include 
randomisation and blinding to limit bias and sample size calculations to ensure 
studies are adequately powered to detect real differences between treatment and 
control groups. Oedema-corrected infarct size should be measured when the lesion 
has reached its maximum size, and not before (i.e. when the infarct is still evolving).  
If significant mortality is encountered prior to this time point, the severity of the 
ischaemic insult should be reduced to limit morbidity and improve survival.  
Information on inclusion/exclusion criteria, excluded animals and mortality should 
be included in pre-clinical stroke publications.  Despite the fact that the first STAIR 
recommendations have now been in press for more than a decade, issues relating to 
preclinical study design and quality are still evident in the literature. A recent 
systematic survey examined all cerebrovascular research studies published in the 
Journal of Cerebral Blood Flow and Metabolism in 2008.  “Few studies reported a 
primary research hypothesis, statement of purpose, or measures to safeguard 
internal validity (such as randomization, blinding, exclusion or inclusion criteria). 
Many studies lacked sufficient information regarding methods and results to form a 
reasonable judgment about their validity.” (Vesterinen et al., 2010).  The 
deficiencies identified are in no way exclusive to the Journal of Cerebral Blood Flow 
and Metabolism.  They are evident throughout the neuroscience literature, and are 
just as prevalent, if not more so, for other neurodegenerative diseases ( Jucker, 
2010, Rooke,  et al. 2011, Macleod 2011).  The survey by Vesterinen and colleagues 
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exemplifies both the major problem and the achievable solution to the pre-clinical 
end of the translational roadblock in stroke research.  There is an onus on 
researchers and manuscript referees to ensure that the basic principles of good 
study design and reporting are adhered to, to bring the pre-clinical literature up to 
the same standards as the clinical literature.  Journal editors have the power to 
improve the standard of pre-clinical publications and should be update instructions 
to authors to make specific statements on study design mandatory. 
 
Journal editors also have the powers to reduce publication bias, another issue which has 
influenced our ability to predict drug efficacy from pre-clinical data. Reluctance to 
publish negative or neutral drug studies has resulted in overestimation of drug efficacy 
and has severely limited the ability of pre-clinical meta-analyses and systematic reviews to 
predict drug efficacy in man (Dirnagl and Macleod, 2009). However, this failing is now 
being addressed with some journal editors recognising the importance of publishing properly 
conducted studies which fail to identify drug efficacy (e.g. a new Negative Results article 
type in the Journal of Cerebral Blood Flow & Metabolism, for data that fails to identify a 
difference between the experimental groups and/or reproduce published findings).  
 
All the focal ischaemia models described require induction of anaesthesia and some 
surgery, both of which can give rise to variability in outcome in neuroprotection studies. 
Anaesthesia can affect blood pressure, blood gases and body temperature, all of which 
influence stroke severity and outcome. In addition, many anaesthetics (e.g. isoflurane, 
halothane, xenon, propofol, ketamine) have inherent neuroprotective characteristics 
(Kawaguchi et al., 2005, Traystman, 2010).  Duration of anaesthesia should therefore be 
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as short as possible. In studies where the whole experiment is carried out in the 
anaesthetised animal, physiological monitoring is recommended to ensure physiological 
parameters stay within normal limits.  This will help to control variability in outcome and 
thereby increase the power to detect a therapeutic effect. Physiological monitoring can 
also be useful in detecting any drug-induced influences on these parameters which could 
either limit or enhance efficacy.  
 
Using a similar format to multi-centre clinical trials,  networks of preclinical 
researchers establishing and using standardised techniques and confirming results 
across centres will achieve much more than individual groups competing for funds.  
A standardised set of tests for assessment of functional outcome from stroke in each 
model, would be a priority to reach agreement on.  
 
In summary, since the positive rt-PA NINDS trial in 1995, many neuroprotective drugs 
have been tested in >114 clinical trials (http://www.strokecenter.org/trials/) but none has 
shown clinical efficacy. This dismal lack of progress has led to a devastating reduction in 
acute stroke research and development programmes within the major pharmaceutical 
companies. Published guidelines provide the steps required to address the limitations in 
study design and reporting on the pre-clinical side and problems with patient selection for 
trials on the clinical side of the translational roadblock.   Addressing these limitations is 
eminently achievable with the establishment of preclinical stroke networks, more 
widespread use of diagnostic imaging and better links between preclinical and clinical 
scientists.  Progress will have significant cost implications, requiring greater numbers of 
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animals (to include aged and comorbidities) and increased use of both pre-clinical and 
clinical imaging.  However, identification of just one neuroprotective /neurorepair 
therapy with clinical efficacy for stroke would more than justify the costs, providing an 
alternative to rt-PA for the majority of patients who are not currently treated, and 
reversing the roadblock by restoring confidence in the pharmaceutical industry for further 
drug development. 
 
Table 1.   Advantages and disadvantages of the different focal ischaemia models. CCAO, 
common carotid artery occlusion, MCAO, middle cerebral artery occlusion. 
 
Table 2.  Published mortality data for different rodent focal ischaemia models.  Some 
data displayed represent figures for vehicle-treated or control groups in pharmacotherapy 
studies.  Mortality levels encountered are dependent not only on the model employed but 
also the survival period and the level of experience and skills of the surgeon. BCCAO. 
Bilateral common carotid artery occlusion,  f, female,  m, male, PMCAO, permanent 
middle cerebral artery occlusion,  SD, Sprague Dawley, TMCAO, transient middle 
cerebral artery occlusion,  # Small burr hole on dorsal surface of the skull for insertion of 
stereotaxic needle and/or guide cannula. 
 
Table 3. MRI techniques used in pre-clinical stroke research. ADC, apparent diffusion 
coefficient, CBF, cerebral blood flow 
 
Figure Legends 
Figure 1   Middle Cerebral Artery Occlusion Models in Rats & Mice. Pink shading on 
MCA territory diagram represents the tissues supplied by the MCA.  Pink shading on the 
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electrocoagulation diagrams represents ischaemia and demonstrates the ability to induce 
purely cortical ischaemia with a distal MCAO versus cortical and subcortical ischaemia 
with a proximal MCAO including the lenticulostriate branches.  
 
Figure 2  Histology & MRI measures of outcome.  a) Haematoxylin and eosin (H&E) 
stained section illustrating the ability to discriminate between irreversibly damaged 
and morphologically normal tissue (  ) in perfusion fixed paraffin 
embedded tissue.  With this level of tissue processing irreversible ischaemic damage 
is distinguished from changes in neuronal morphology and background neuropil  
which becomes irregular and vacuolated as early as 4 hours after permanent 
MCAO.  Higher magnification inset panels show the characteristic morphology of 
dark, shrunken,  pyknotic,  ischaemically damaged neurone cell bodies (top left), 
compared to the  pale stained,  round morphology of normal neuronal cell bodies 
(bottom right). b) by 24 hours  after permanent MCAO, a low magnification image  
of a fresh frozen cryostat section stained with  H&E will clearly display the 
boundary between infarct (area of palor on RHS of section) and non-ischaemic 
tissue. Note also the brain swelling evident in the ipsilateral hemisphere. c) by 24 
hours  after permanent MCAO, triphenyltetrazolium chloride (TTC) staining of 
fresh tissue slices will also reveal a clear boundary between infarct (white) and non-
iscaemic tissue (red). d-f these MRI scans are non-invasive and do not require 
administration of contrast agents. d) arterial spin labelling provides serial scans of 
cerebral blood flow to map the severity and location of ischaemia. e) diffusion-
weighted imaging (DWI) provides serial scans of ischaemic injury (hyperintensity), 
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which in the first hours after stroke may be reversible on reperfusion. f)  T2-
weighted imaging identifies infarct (hyperintensity) from 24 hours post-stroke. 
  
Figure 3.  Behavioural tests in rodent stroke models. Illustrations of four commonly 
used sensorimotor tests. The cylinder test reveals forelimb preference when the 
animal rears to explore its environment by making forelimb contact with the 
cylinder walls. The horizontal ladder and tapered beam tests  reveals foot faults 
(orange arrows) as the animal traverses the ladder, which has irregularly spaced 
rungs, or the beam which gets gradually  narrower as the animal approaches its 
home cage.  
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Model Advantages Disadvantages 
   
MCA permanently occluded by  
electrocoagulation  
 
Good reproducibility in outcome measures achievable.  
Successful MCAO confirmed visually by section of the 
occlusion site. 
Some control over infarct size and location possible by 
occluding different segments of the MCA. 
Infarct matures quickly and is maximal within 24-48 hours. 
Requires craniectomy, technically challenging. 
Model not suitable for transient ischaemia 
thrombolysis studies. 
 
  
 Low mortality.  
   
MCA occluded by an intraluminal 
filament  
Good reproducibility in outcome measures achievable. 
Suitable for permanent or transient ischaemia. 
Technically straightforward surgery (no craniectomy) 
Successful MCAO cannot be confirmed visually
Reproducibility dependent on identifying the 
optimal filament dimensions and construction for
the rodent strain and size used. 
  Increased haemorrhage risk with certain filament
types.  
Significant mortality may be encountered with 
large strokes (> 24 hours) & before infarct has 
fully evolved  
  Model not suitable for thrombolysis studies 
   
MCA occluded by endothelin-1 
(topical or intraparenchymal) 
Good reproducibility in outcome measures achievable. 
Successful MCAO can be confirmed visually (topical 
model).  
Dependent on  endothelin-1 vasoconstrictor 
potency being consistent from batch to batch 
 Modifications to intraparenchymal model allow ischaemia 
induction in conscious rat. 
Topical administration requires craniectomy. 
Models not suitable for thrombolysis studies 
   
MCA occluded by clip/mechanical 
device 
Successful MCAO is confirmed visually.  
Suitable for permanent or transient ischaemia. 
Requires craniectomy, technically challenging an
likely to require more than one occlusion site, 
hypotension or CCAO to achieve reproducibility
   
MCA occluded by autologous blood Most closely mimics human ischaemic stroke. Less reproducible than other models. 
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clot Model suitable for thrombolysis studies.  Less control over ischaemia location and duration
More variability in outcome measures.  
Secondary microclot formation possible with clo
breakdown 
  Higher mortality than for other models 
   
MCA branch occluded by 
intravascular thrombin injection 
Reproducibility in cortical ischaemia and infarct volume 
achievable.  
Position and persistence of clot confirmed visually.  
Requires craniectomy. 
Secondary microclot formation possible with clo
breakdown 
 Model suitable for thrombolysis studies.  
Low mortality compared to autologous clot models. 
Limited sensorimotor deficit due to small size an
location of infarct 
  . 
Photochemical ischaemia Reproducibility in cortical ischaemia and infarct volume 
achievable.  
Blood vessel thrombosis can be achieved through intact 
skull.  
More recent modifications of the model are suitable for 
thrombolysis studies 
 
Photocoagulation insult causes severe damage to
affected blood vessels and substantial early 
vasogenic oedema uncharacteristic of human 
stroke. 
Limited sensorimotor deficit due to small size an
location of infarct 
 
 
 
Table 1   Advantages and disadvantages of the different focal ischaemia models.  CCAO, common carotid artery occlusion, MCAO, middle cerebral 
artery occlusion. 
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 MCAO Model 
 (duration of ischaemia) 
Species, Strain 
(m/f) 
Craniectomy 
 
Mortality 
(time period examined) 
References 
     
Proximal MCAO (permanent) 
Electrocoagulation 
Rat, Wistar (m) Yes 0% (10 weeks) Yonemori et al., 1999 
Proximal MCAO (permanent )  
Intraluminal filament 
 
Rat, SD (m) 
Rat SD (m) 
Rat SD (m) 
Rat Wistar (m) 
Rat Fischer 344 (m) 
No 
No 
No 
No 
No 
18.2% (24 hrs) 
42% (72 hrs) 
0% (24 hrs), 12.5-33%* (48 hrs) 
75% (24 hours) 
8%  (24 hours) 
Lu et al., 2009 
Schöller et al. 2004 
Aspey et al., 1998 
Aspey et al., 1998 
Aspey et al., 1998 
Distal MCAO (permanent) 
Electrocoagulation 
Mouse, C57BL/6 (m) Yes 0% (6hrs-8 days) Kuraoka , et al, 2009 
TMCAO (proximal, 60 mins) 
Ligature + BCCAO 
Rat SD (m) young, 3-4 
months  
Rat SD (m) old, 22-24 
months 
Yes 
Yes 
6.3% (24hrs), 6.3% (28 days) 
35% (24 hrs), 43.5% (28 days) 
Wang et al., 2003 
TMCAO Intraluminal filament 
(proximal, 60 mins) 
(proximal, 45 mins) 
 
Mouse, SV129/J (m) 
Mouse, 129S6SvEv (m) 
 
No 
No 
 
13, 37 & 57% (4, 5 & 6 days, resp) 
33% (72 hrs) 
 
Meisel et al., 2004 
Braun et al., 2007 
Thromboembolic  
(autologous clot) 
Rat  SD 
Rat SD (m) 
No 
No 
30-50% (24 hrs) 
44% (14 days) 
Orset et al. 2010 
Rasmussen et al., 2008 
Thromboembolic  
(intra-arterial thrombin injection) 
Mouse, Swiss (m)  Yes <1% (24hrs and 3 months ) Orset et al. 2010 and 
Vivien D, personal 
communication  
Photochemical stroke Mouse and rat No Low (not defined)  Witte (2010) 
Endothelin-1 topical application 
to MCA 
 
Endothelin-1 injection into 
piriform cortex adjacent to 
proximal MCA    
 
Rat SD (m) 
 
 
Rat SD (m) 
 
Yes 
  
 
# 
  
<5% (4 hrs) 
 
 
7% (24 hrs), thereafter 0% out to 3 months  
 
15% (4 hrs) 
 
Macrae IM , unpublished 
 
 
Sharkey J (personal 
communication) 
Nikolova et al., 2009 
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Table 2.  Published mortality data for different rodent focal ischaemia models.  Mortality levels encountered are dependent not only on the model 
employed but also the survival period and the level of experience and skills of the surgeon. BCCAO. Bilateral common carotid artery occlusion,  f, 
female,  m, male, MCAO, middle cerebral artery occlusion,  SD, Sprague Dawley, TMCAO, transient middle cerebral artery occlusion, * dependent 
on suture used,  # Small burr hole on dorsal surface of the skull for insertion of stereotaxic needle and/or guide cannula. 
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MRI Technique  Potential use in pre-clinical stroke research  
  
MR Angiography Occlusion/patency status of the targeted blood vessel 
Perfusion-weighted imaging  PWI Serial CBF maps reveal severity and location of ischaemia, and any spontaneous or 
induced reperfusion or drug-induced changes in CBF 
Diffusion-weighted imaging DWI Serial DWI and ADC maps reveal acute and evolving brain injury, brain swelling  
PWI/DWI mismatch  Serial assessment of penumbra and its incorporation into ischaemic core over time.  
Functional MRI (fMRI) combined with a 
stimulus such as forepaw stimulation 
Serial fMRI studies combined with a specific stimulus will  reveal ischaemia-induced 
loss of function in response to the stimulus, any compensatory changes  or subsequent 
return of function 
Contrast-enhanced T1-weighted imaging Blood-brain barrier breakdown    
T1, T2  and T2*-weighted imaging Brain haemorrhage 
Diffusion tensor imaging -DTI White matter damage 
T2-weighted imaging Infarct, brain swelling     
 
Table 3  MRI techniques used in pre-clinical stroke research. ADC, apparent diffusion coefficient, CBF, cerebral blood flow.  
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